132 related articles for article (PubMed ID: 7192096)
1. Characterization of a new potent heparin. 5th Communication: Further characterization by affinity chromatography on antithrombin-sepharose and its comparison with a commercially available heparin.
Bhargava AS; Freihube G; Günzel P
Arzneimittelforschung; 1980; 30(10):1621-3. PubMed ID: 7192096
[TBL] [Abstract][Full Text] [Related]
2. An improved method for removal of antithrombin III from post-heparin plasma lipase fractions with a high recovery rate.
Moriguchi EH; Tamachi H; Homma Y; Goto Y
Tokai J Exp Clin Med; 1991 Mar; 16(1):33-41. PubMed ID: 1780907
[TBL] [Abstract][Full Text] [Related]
3. Isolation and characterization of heparin from human lung.
Metcalfe DD; Lewis RA; Silbert JE; Rosenberg RD; Wasserman SI; Austen KF
J Clin Invest; 1979 Dec; 64(6):1537-43. PubMed ID: 500822
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological activities of heparins obtained from different tissues: enrichment of heparin fractions with high lipoprotein lipase, antihemolytic and anticoagulant activities by molecular sieving and antithrombin III affinity chromatography.
Bianchini P; Osima B; Parma B; Nader HB; Dietrich CP
J Pharmacol Exp Ther; 1982 Feb; 220(2):406-10. PubMed ID: 7057400
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a new potent heparin. 1 communication: Determinations of anticoagulant activity of a high potency heparin preparation in vivo using dog as an experimental animal and in vitro using dog and human plasma.
Bhargava AS; Heinick J; Schöbel C; Günzel P
Arzneimittelforschung; 1980; 30(6):993-6. PubMed ID: 7191280
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulant activity of heparin: separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin.
Höök M; Björk I; Hopwood J; Lindahl U
FEBS Lett; 1976 Jul; 66(1):90-3. PubMed ID: 1278445
[No Abstract] [Full Text] [Related]
7. Isolation and characterization of heparin from human mastocytoma tissue.
Thunberg L; Höök M; Lindahl U; Abildgaard U; Langholm R
Thromb Haemost; 1980 Dec; 44(3):125-9. PubMed ID: 6781095
[TBL] [Abstract][Full Text] [Related]
8. High and low anticoagulant activity heparins. Preparation in large scale and degree of complexation with antithrombin III.
Takahashi HK; Nader HB; Dietrich CP
Arzneimittelforschung; 1985; 35(11):1620-3. PubMed ID: 4091864
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a new potent heparin. 2nd communication: Chemical analysis of the carbohydrate content and determination of the biological activity of a new potent heparin preparation in vitro, using protamine neutralization and amidolytic methods for factor Xa and thrombin.
Bhargava AS; Heinick J; Günzel P
Arzneimittelforschung; 1980; 30(7):1071-4. PubMed ID: 7191289
[TBL] [Abstract][Full Text] [Related]
10. Separation of heparin into subfractions by DEAE-cellulose chromatography.
Yue RH; Starr T; Gertler MM
Thromb Haemost; 1980 Feb; 42(5):1452-9. PubMed ID: 7368152
[TBL] [Abstract][Full Text] [Related]
11. Binding to antithrombin of heparin fractions with different molecular weights.
Danielsson A; Björk I
Biochem J; 1981 Feb; 193(2):427-33. PubMed ID: 7305940
[TBL] [Abstract][Full Text] [Related]
12. Polysaccharides from the skin of the ray Raja radula. Partial characterization and anticoagulant activity.
Ben Mansour M; Majdoub H; Bataille I; Roudesli MS; Hassine M; Ajzenberg N; Chaubet F; Maaroufi RM
Thromb Res; 2009 Feb; 123(4):671-8. PubMed ID: 18617224
[TBL] [Abstract][Full Text] [Related]
13. Selective cleavage of heparin using aqueous 2-hydroxypyridine: production of an aldose-terminating fragment with high anticoagulant activity.
Berry LR; Parmar N; Hatton MW; Chan AK
Biochem Biophys Res Commun; 2006 Aug; 346(3):946-57. PubMed ID: 16781674
[TBL] [Abstract][Full Text] [Related]
14. Medium format enhancement: design of an immobilized heparin affinity media for industrial bioprocessing.
Kennedy RM
J Mol Recognit; 1997; 10(2):88-92. PubMed ID: 9376131
[TBL] [Abstract][Full Text] [Related]
15. Commercial antithrombin concentrate contains inactive L-forms of antithrombin.
Chang WS; Harper PL
Thromb Haemost; 1997 Feb; 77(2):323-8. PubMed ID: 9157590
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a new potent heparin. 3rd Communication: Determinations of anticoagulant activity of a new potent heparin preparation by thrombelastography in vitro using citrated dog and human blood.
Bhargava AS; Freihube G; Günzel P
Arzneimittelforschung; 1980; 30(8):1256-8. PubMed ID: 7192139
[TBL] [Abstract][Full Text] [Related]
17. The antithrombin-binding sequence in heparin. Identification of an essential 6-O-sulfate group.
Lindahl U; Bäckström G; Thunberg L
J Biol Chem; 1983 Aug; 258(16):9826-30. PubMed ID: 6885772
[TBL] [Abstract][Full Text] [Related]
18. Location of antithrombin-binding regions in rat skin heparin proteoglycans.
Jacobsson KG; Lindahl U; Horner AA
Biochem J; 1986 Dec; 240(3):625-32. PubMed ID: 3827857
[TBL] [Abstract][Full Text] [Related]
19. Pasteurization of antithrombin without generation of the prelatent form of antithrombin.
Karlsson G
Protein Expr Purif; 2004 Jun; 35(2):381-6. PubMed ID: 15135417
[TBL] [Abstract][Full Text] [Related]
20. Preparation and partial characterization of human plasma depleted of antithrombin-III by heparin-sepharose affinity chromatography.
Hoogendoorn H; Cerskus A; Ofosu F; Blajchman M; Hirsh J
Thromb Res; 1980 Oct; 20(1):77-83. PubMed ID: 7209874
[No Abstract] [Full Text] [Related]
[Next] [New Search]
